http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PolyPid Ltd. (PYPD) Receives Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
-
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
-
PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds
-
PolyPid Ltd. (PYPD) Prices 6.2M Share Offerings at $0.42/sh, Concurrent $4.4M Placement of Pre-Funded Warrants
-
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
-
PolyPid Ltd. (PYPD) Announces Proposed Share Offering
-
PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
-
PolyPid to Present at the Barclays Global Healthcare Conference
-
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
-
PolyPid (PYPD) Provides Positive Regulatory Update for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
-
PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
-
PolyPid Ltd. (PYPD) announces publication of a post-hoc analysis from the previously-completed Phase 2 study of D-PLEX100
-
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
-
PolyPid Ltd. (PYPD) Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX100 for the Prevention of Surgical Site Infections i
-
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal
-
PolyPid (PYPD) Announces Receipt of Nasdaq Minimum Bid Price Notification
-
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
-
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
-
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022
-
PolyPid Ltd. (PYPD) Announces Cost Reduction Plan
-
PolyPid Announces Cost Reduction Plan
-
PolyPid Ltd. (PYPD) Announces Eligibility for EMA Centralized Procedure for D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery
-
PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
-
PolyPid Ltd. (PYPD) Reports Publication of Phase 2 Clinical Trial Results for D-PLEX
-
PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
-
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference
-
PolyPid Ltd. (PYPD) Sinks as Phase 3 SHIELD I Trial of D-PLEX100 Didn't Achieve Statistical Significance
-
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
-
PolyPid Announces Presentation at the 2022 Military Health System Research Symposium
-
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe
-
PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022
-
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
-
PolyPid (PYPD) Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
-
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
-
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections
-
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
-
PolyPid to Present at the JMP Securities 2022 Life Sciences Conference
-
PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence wit
-
PolyPid Ltd. (PYPD) Completes Enrollment of SHIELD I Phase 3 Study of D-PLEX100
-
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery
-
PolyPid Ltd. (PYPD) Reports Data Safety Monitoring Board Recommended to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted
-
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Inte
-
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022
-
PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine
-
PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting
-
PolyPid Ltd. (PYPD) Announces $15M Non-Dilutive Secured Term Loan Facility with Kreos Capital VI
